Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$23.34 USD
-0.15 (-0.64%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $23.33 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.34 USD
-0.15 (-0.64%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $23.33 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Zacks News
Dentsply International (XRAY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
Align (ALGN) Unveils New Product for Better Treatment Option
by Zacks Equity Research
Align Technology's (ALGN) latest product to aid in improving doctor performance and ensure better treatment planning.
Dentsply (XRAY) Up 3.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY (XRAY) continues to gain traction from its solid focus on R&D leading to product innovation, which continues to be a key catalyst.
DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2020 results reflect weak segmental performance.
Dentsply International (XRAY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -500.00% and -3.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect weak segmental performance.
Dentsply International (XRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Near-Term Outlook Bleak for Medical Dental Supplies Industry
by Trina Mukherjee
Digital influence coupled with AI & Robotics can drive the medical dental supplies industry amid the coronavirus-induced crisis.
New Strong Sell Stocks for June 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Dentsply (XRAY) Up 22.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for June 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2020 preliminary results reflect weak segmental performance and decline in revenues.
Dentsply International (XRAY) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 4.88% and -0.29%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) first-quarter performance to reflect focus on product innovation and R&D.
Earnings Preview: Dentsply International (XRAY) Q1 Earnings Expected to Decline
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
First US Payroll Crash Since 2010: What's Hot, What's Not
by Sanghamitra Saha
U.S. payroll numbers in March were lackluster. We have highlighted a few industries that survived the coronavirus threat in March and also the ones that succumbed.
Dentsply (XRAY) Down 17.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Align Technology to Acquire exocad in Digital Dentistry Space
by Zacks Equity Research
This acquisition is expected to boost Align Technology's (ALGN) portfolio of Invisalign and iTero digital solutions.
DENTSPLY SIRONA (XRAY) Q4 Earnings Lag Estimates, Sales Rise
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) gains from the Technologies & Equipment arm in Q4.
Dentsply International (XRAY) Q4 Earnings Lag Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -1.35% and 2.11%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
STERIS' (STE) Growth Picture Impressive Amid Rising Costs
by Zacks Equity Research
STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?